Urologic Oncology
The Urologic Oncology program within the Department of Urology at Wake Forest University Baptist Medical Center is committed to providing state-of-the-art, multidisciplinary care to patients with genitourinary malignancies. Our activities are an integral component of Wake Forest Baptist’s Comprehensive Cancer Center. Last year there were 3,014 urology clinic visits and 1,009 surgical procedures performed for patients with urologic cancers.
The Urologic Oncology program brings together clinicians from multiple departments to provide multidisciplinary cancer care and innovative clinical trials. In addition to physicians within the Department of Urology, core members of the Genitourinary Oncology program are:
· Frank M. Torti, M.D., Professor, Hematology and Oncology,Charles L. Spurr, Professor of Medicine; Chairman, Department of Cancer Biology; Director, Comprehensive Cancer Center
· Ronald J. Zagoria, M.D.; Professor, Radiology; Section Head, Abdominal Radiology
· Ralph D. Woodruff, M.D., Associate Professor, Pathology
· Gary Schwartz, Ph.D., Associate Professor, Cancer Biology and Public Health Sciences; Director of the Prostate Cancer Center of Excellence
This group diagnoses, stages, treats, and follows-up with patients who have tumors of the prostate, bladder, kidney/ureter, testis, and other genitourinary sites. The Urologic Oncology program also supports numerous in-house and cooperative oncology group trials through the Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG). Through these mechanisms, patients have access to clinical trials for most genitourinary malignancies that incorporate multiple modalities of treatment to effect the best possible outcome. In addition to the clinical activities noted above, this group also supports through additional collaborations significant translational and basic research efforts in urologic oncology.